loading  Checking for direct PDF access through Ovid



The aim of the study was to evaluate the impact of cholecalciferol supplementation on blood pressure (BP) in patients with arterial hypertension (AH) stage II.

Design and method:

A prospective, cohort, single-center study of 144 individuals with stage II AH (50.6 ± 7.3 years) was performed. Antihypertensive therapy was administered according to 2013 ESH/ESC guidelines for the management of AH. In addition to antihypertensive therapy every second patient on the alphabetical list was recommended to take cholecalciferol 2,000 IU/day daily. The duration of cholecalciferol supplementation was 4.4 ± 2.2 months. The serum level of 25(OH)D total (ng/ml) was determined by the immunoenzymatic assay using the DRG reagent (Germany, Marburg). The duration of follow-up was 15.8 ± 1.8 months. The “dynamics” (d) index was calculated as a difference between values before and after administered therapy.


At baseline office systolic (SBP) and diastolic BP (DBP) averaged at 150[140;160]/90[90;100] mmHg. On the follow-up there were their significant (p < 0,0001) reduction and were 130[125;140]/80[80;90] mmHg correspondingly. Target levels of office BP measurements were achieved in 83.9% for SBP and 87.1% for DBP. Serum 25(OH)D total at baseline was 24.8[17.02; 34.06] ng/ml, at the end of the follow-up period – 41.7[33.1; 53.5] ng/ml (p = 0.00001). We established a significant influence of cholecalciferol supplementation on dSBP (F = 4.1; p = 0.046). Correlation relationship between dSBP and duration of cholecalciferol intake was established (R = 0.42; p = 0.023). It was found that intake of diuretics (hydrochlorothiazide at a dose of 12.5 mg and higher, or indapamide 1.5 mg or higher) as part of combination of antihypertensive therapy influenced the dynamics of serum 25(OH)D (F = 5.35;p = 0.02) and its level (F = 11.8; p = 0.0009). The highest d25(OH)D was found in the group of patients without diuretics intake. dSBP value was highest (−27.4 ± 17.9) in the group receiving diuretics and cholecalciferol, which was significantly (p < 0.001) different from the comparison group.


The combined use of cholecalciferol at a dose of 2000 IU/day and diuretic in the treatment of patients with AH stage II allowed to obtain the greatest hypotensive effect on SBP.

Related Topics

    loading  Loading Related Articles